These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

137 related items for PubMed ID: 12468925

  • 1. Use of hydroxyurea and recombinant erythropoietin in management of homozygous beta0 thalassemia.
    Kohli-Kumar M, Marandi H, Keller MA, Guertin K, Hvizdala E.
    J Pediatr Hematol Oncol; 2002 Dec; 24(9):777-8. PubMed ID: 12468925
    [Abstract] [Full Text] [Related]

  • 2. Hemoglobin switching protocols in thalassemia. Experience with sodium phenylbutyrate and hydroxyurea.
    Dover GJ.
    Ann N Y Acad Sci; 1998 Jun 30; 850():80-6. PubMed ID: 9668530
    [Abstract] [Full Text] [Related]

  • 3. Therapeutic superiority and safety of combined hydroxyurea with recombinant human erythropoietin over hydroxyurea in young β-thalassemia intermedia patients.
    Elalfy MS, Adly AA, Ismail EA, Elhenawy YI, Elghamry IR.
    Eur J Haematol; 2013 Dec 30; 91(6):522-33. PubMed ID: 23927461
    [Abstract] [Full Text] [Related]

  • 4. Hydroxyurea therapy in thalassemia.
    Loukopoulos D, Voskaridou E, Stamoulakatou A, Papassotiriou Y, Kalotychou V, Loutradi A, Cozma G, Tsiarta H, Pavlides N.
    Ann N Y Acad Sci; 1998 Jun 30; 850():120-8. PubMed ID: 9668534
    [Abstract] [Full Text] [Related]

  • 5. On the use of hydroxyurea/erythropoietin combination therapy for sickle cell disease.
    el-Hazmi MA, al-Momen A, Kandaswamy S, Huraib S, Harakati M, al-Mohareb F, Warsy AS.
    Acta Haematol; 1995 Jun 30; 94(3):128-34. PubMed ID: 7502628
    [Abstract] [Full Text] [Related]

  • 6. Pharmacologic manipulation of fetal hemoglobin levels in sickle cell diseases and thalassemia: promise and reality.
    Pearson HA.
    Adv Pediatr; 1996 Jun 30; 43():309-34. PubMed ID: 8794181
    [No Abstract] [Full Text] [Related]

  • 7. Comparison of efficacy and safety of thalidomide vs hydroxyurea in patients with Hb E-β thalassemia - a pilot study from a tertiary care Centre of India.
    Jain M, Chakrabarti P, Dolai TK, Ghosh P, Mandal PK, Baul SN, De R.
    Blood Cells Mol Dis; 2021 May 30; 88():102544. PubMed ID: 33610115
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Experience with combination of hydroxyurea and low-dose thalidomide in transfusion-dependent beta thalassemia patients.
    Bhurani D, Kapoor J, Yadav N, Khushoo V, Agrawal N, Ahmed R, Arora JS, Mehta P.
    Ann Hematol; 2021 Jun 30; 100(6):1417-1427. PubMed ID: 33811502
    [Abstract] [Full Text] [Related]

  • 10. Report on patients with non transfusion-dependent β-thalassemia major being treated with hydroxyurea attending the Thalassemia Research Center, Sari, Mazandaran Province, Islamic Republic of Iran in 2013.
    Kosaryan M, Karami H, Zafari M, Yaghobi N.
    Hemoglobin; 2014 Jun 30; 38(2):115-8. PubMed ID: 24471558
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Reduction of the clinical severity of sickle cell/beta-thalassemia with hydroxyurea: the experience of a single center in Greece.
    Loukopoulos D, Voskaridou E, Kalotychou V, Schina M, Loutradi A, Theodoropoulos I.
    Blood Cells Mol Dis; 2000 Oct 30; 26(5):453-66. PubMed ID: 11112383
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Combination therapy of erythropoietin, hydroxyurea, and clotrimazole in a beta thalassemic mouse: a model for human therapy.
    de Franceschi L, Rouyer-Fessard P, Alper SL, Jouault H, Brugnara C, Beuzard Y.
    Blood; 1996 Feb 01; 87(3):1188-95. PubMed ID: 8562946
    [Abstract] [Full Text] [Related]

  • 16. Long-term safety and efficacy of hydroxyurea in patients with non-transfusion-dependent β-thalassemia: a comprehensive single-center experience.
    Karimi M, Zarei T, Bahmanimehr A, Aramesh A, Daryanoush S, Haghpanah S.
    Ann Hematol; 2021 Dec 01; 100(12):2901-2907. PubMed ID: 34383102
    [Abstract] [Full Text] [Related]

  • 17. Single and combination drug therapy for fetal hemoglobin augmentation in hemoglobin E-beta 0-thalassemia: Considerations for treatment.
    Singer ST, Kuypers FA, Olivieri NF, Weatherall DJ, Mignacca R, Coates TD, Davies S, Sweeters N, Vichinsky EP.
    Ann N Y Acad Sci; 2005 Dec 01; 1054():250-6. PubMed ID: 16339672
    [Abstract] [Full Text] [Related]

  • 18. Response to hydroxycarbamide in pediatric β-thalassemia intermedia: 8 years' follow-up in Egypt.
    El-Beshlawy A, El-Ghamrawy M, EL-Ela MA, Said F, Adolf S, Abdel-Razek AR, Magdy RI, Abdel-Salam A.
    Ann Hematol; 2014 Dec 01; 93(12):2045-50. PubMed ID: 25062719
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Hydroxyurea therapy in children severely affected with sickle cell disease.
    Scott JP, Hillery CA, Brown ER, Misiewicz V, Labotka RJ.
    J Pediatr; 1996 Jun 01; 128(6):820-8. PubMed ID: 8648542
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.